KLK3 and prostate carcinoma: It is important to note that progression-free survival (PFS) is a poor intermediate endpoint of overall survival in prostate cancer, with overall associations between PFS and overall survival at best moderate (0.4 for radiographic PFS and 0.33 for PSA PFS) [21].